Apretude
Apretude is the brand name for cabotegravir, a long-acting injectable antiretroviral medication approved for HIV pre-exposure prophylaxis (PrEP). Cabotegravir is an integrase strand transfer inhibitor (INSTI) that blocks HIV replication. Apretude is indicated to reduce the risk of acquiring HIV-1 infection in adults and in certain at-risk adolescents, in combination with HIV testing and counseling, and is not intended for treatment of HIV infection. It should not be used if HIV infection is present.
Dose and administration: Apretude is given as a deep intramuscular injection into the gluteal muscle. The regimen
Effectiveness: In large clinical trials, cabotegravir PrEP demonstrated high efficacy in preventing HIV infection and was
Safety and side effects: The most common adverse events are injection-site reactions such as pain, swelling,
Regulatory status: Apretude received FDA approval in December 2021 and has been incorporated into PrEP guidelines